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INTRODUCTION
     Human immunodeficiency virus (HIV) infection / Acquired immune deficiency 
syndrome (AIDS) is a global pandemic 1 and is the most important public health 
problem of the 21 st century2,3.  Though HIV made a delayed entry into India in 
1986 its spread has been very rapid and at present is in an advanced stage of  
the pandemic in some states of our country 4,5.  
     India has a population of one billion with HIV infection spreading among them 
at an increasing rate. The spread of HIV in India has been diverse with much of  
India having a low rate of infection and the epidemic being most extreme in the 
southern  half  of  the  country  and  in  the  far  north-east.   The  highest  HIV 
prevalence  rates  are  found  in  Maharashtra,  Andhra  Pradesh,  Karnataka, 
Nagaland, Gujarat, Tamil Nadu,  Manipur and West Bengal. 
     The Indian National AIDS control organization (NACO) estimates that 5.21 
million people were living with HIV in 2005 giving an adult prevalence of 0.91%. 
It also estimates that 111,608 people were living with AIDS at the end of July  
2005  6 and  the  average  HIV  prevalence  among  women  attending  antenatal 
clinics in India is 0.88% and in Tamil Nadu is 0.5%7 .  
     HIV is unique among human viral infections.  Once infection has established,  
the virus succeeds in escaping immune mediated clearance and is virtually never 
eliminated from the body.  A chronic infection develops that persists with varying  
degrees of viral replication for a longer period along with progressive qualitative 
and quantitative deficiency of the subset of T-lymphocytes which leads to gradual 
loss  of  immune  system  functions  and  predisposes  to   several  opportunistic 
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infections particularly respiratory infections due to various bacterial  and fungal 
pathogens8 which account  for 70% of AIDS defining illness9-11      
     Lower respiratory tract infections are an important cause of morbidity and 
mortality in all age groups in HIV patients12.  In India it has been reported that 
respiratory  infections  account  for  20  –  40%  of  outpatient  and  12  –  35%  of 
inpatient attendance in a general hospital in HIV patients13,14.  Since the etiologic 
agents  of  lower  respiratory  tract  infections  cannot  be  determined  clinically 
microbiological investigations are critical for both treatment and epidemiological  
purposes  as  lower  respiratory  tract  infections  form  an  important  part  of 
opportunistic infections in HIV infected persons15-17.
          In our hospital we have also noticed an increasing incidence of lower 
respiratory tract infections in HIV infected patients.   This led us to conduct a 
prospective study in order to record clinical and microbiological observations and 
to find out the bacterial and fungal etiology of lower respiratory tract infections in  
HIV seropositive patients.  
      We also did this study to find the incidence of mycoplasma infection in lower  
respiratory tract infections in HIV seropositive patients as mycoplasma species 
act as important cofactors in HIV infection.
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AIMS AND OBJECTIVES
1. To evaluate  the  bacterial  and fungal  etiology of  lower  respiratory  tract  
infections in the HIV sero-positive patients.
2. To study the incidence of Mycoplasma pneumoniae among the bacterial 
isolates
3. To ascertain  the   significance of  serology in  diagnosis  of  Mycoplasma 
pneumoniae infection in HIV sero-positive patients.
4. To study  the various haematological and clinico-radiological findings in 
lower respiratory tract infections in HIV sero-positive patients.
5. To assess the antibiotic susceptibility pattern of various bacterial isolates 
in HIV sero-positive patients.
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REVIEW OF LITERATURE
     Pulmonary  disease  is  the  first  clinical  presentation  and  most  frequent 
complication of HIV infection and the most common manifestation of pulmonary 
disease is the lower respiratory tract infection particularly pneumonia  of bacterial 
etiology.  The incidence and severity of lower respiratory tract infections(LRTI) 
increase  with  degree  of  immunosuppression1.   At  the  acquired  immuno 
deficiency syndrome stage the responsible bacteria and clinical presentation may 
be atypical18,19.   Bacterial  and fungal  pneumonias may be fatal  particularly  in 
AIDS and its occurrence is predictive of a reduced survival time. 
      HIV associated respiratory infections include upper respiratory tract infections 
i.e. acute or chronic sinusitis, pharyngitis and lower respiratory tract infections – 
acute or chronic bronchitis, pneumonias1. These are prevalent during all stages 
of HIV infection. Many cases of LRTI in HIV patients present with high frequency 
of bacteremia, unusual radiographic abnormalities, high rate of pleural effusions 
and bacterial pneumonias due to opportunistic bacteria and hence these cases 
have to be studied.20
 Risk factors for LRTI
        The most important risk factor is the degree of immunosuppression as 
reflected by the CD4 + T lymphocyte count.  Acute bronchitis is highly prevalent 
during all  stages of HIV disease whereas pneumonias were clearly related to 
decreased  CD4  count.21,22  A  similar  relationship  between  a  decreased  CD4 
count and an increased risk of LRTI has also been found in European studies.23,24 
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     Hirschtick et al 25showed that the risk was greater in intra venous drug users 
than in homosexual male or female partners.  In the same study tobacco was 
equally shown to be an independent risk factor in the subgroup of HIV sero-
positive subjects with < 200 CD4 lymphocytes/mm3.  
     Another risk factor is neutropenia which may result  from direct retroviral  
infection, the use of antiretroviral and other drug therapy, systemic opportunistic 
infections and autoimmune mechanisms. 26Splenectomy,27,28 previous pneumonia 
whatever the cause 29  and smoking illicit drugs have also been associated with 
bacterial pneumonia.  
     Regarding specifically nosocomial pneumonia, advanced HIV infection, CNS 
diseases  have  been  shown  to  be  risk  factors  in  the  case  control  study  of 
Tumbarello et al30.
Bacterial and fungal etiology of LRTI           
   The following  pyogenic bacteria and fungi have been recognized to be a major  
cause of lower respiratory tract infection10,11 in HIV infected patients whatever 
their level of immunosuppression 1.    
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TABLE 1 - Bacterial and fungal etiology of LRTI
               
Infection Common Less common
Bacteria
Mycobacteria
Mycoplasma
Fungi
Streptococcus pneumoniae
Haemophillus influenzae
Staphylococcus aureus
Pseudomonas aeruginosa
Mycobacterium tuberculosis
Mycoplasma pneumoniae
Pneumocystis carini
Histoplasma capsulatum
Cryptococcus neoformans
Aspergillus species
Moraxella
Legionella
Rhodococcus equi
Nocardia
M. avium intracellulare
M. kansasii
M. Xenopi
Mycoplasma fermentans
Mycoplasma pirum
Mycoplasma penetrans
Mycoplasma genitalium
Candida albicans
Coccidioides immitis
Penicillium marneffei
Blastomyces dermatitidis
Incidence of bacterial Lower respiratory tract infection
     The true incidence of LRTI in HIV infected patients is difficult to assess and 
varies with the population surveyed9.  Acute bronchitis and bacterial and fungal 
pneumonias are the most common respiratory diseases of HIV infected patients. 
The respective incidence per 100 person years were 13.7 for bronchitis and 5.5 
for pneumonias.  When HIV infected individuals were compared with controls of 
similar age race, sex and transmission group, the incidence rates were two fold 
greater for bronchitis and six fold greater for pneumonias21. 
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      In intra venous drug users the incidence of pneumonia per 100 person years 
was 1.93 in HIV sero-positive and 0.45 in HIV sero-negative subjects29. Boschini 
et al23 reported 149 episodes of community acquired pneumonia( CAP) among 
HIV  sero-positive  patients  and  61  among  HIV  sero-negative   subjects  with  
incidence  rates  per  1,000  person  years  of  90.5  and  14.2  respectively.   The 
incidence rates of pneumonia per 1,000 person years were 38.6 in HIV sero-
positive females and 3.7 in HIV sero-negative females in Nairobi, Kenya among 
female  sex  workers.   More  precisely,  the  incidence  rates  of  invasive 
pneumococcal disease and pneumococcal bacteraemia per 1,000 person years 
were 42.5 and 23.8 in HIV sero-positeve females and 3.7 and 0 in HIV sero-
negative  females respectively18.   The relative risk of  development of  invasive 
pneumococcal disease with underlying HIV infection was 17.8 (95% confidence 
interval 2.5 – 126.5).  Pyogenic bacteria as well as Mycobacterium tuberculosis 
were  recognized  as  major  cause  of  respiratory  diseases  in  HIV  infected 
Africans30-32.
     The first series investigating bacterial pneumonia in patients with AIDS or 
ARC have shown the predominant role of Streptococcus pneumoniae and to a 
lesser  degree,  Haemophilus  influenzae,  in  adults  as  well  as  children33 in 
developing countries 32-34 and developed contries35-38.  Subsequently other series 
with greater number of patients followed up over a long period have emphasized 
that other bacteria have also been the cause in HIV infected patients.
     Typical pyogenic bacteria more particularly S. pneumoniae and H. influenzae 
were the major responsible bacteria.  In a French clinical epidemiology database, 
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S.  pneumoniae  and  H.  influenzae  were  the  cause  of  52  and  16%  of 
bacteriologically confirmed pneumonia respectively39.  Hirschtick et al 25,found  S. 
pneumoniae  and  H.  influenzae  in  52  and  15%  of  patients  with  confirmed 
pneumonia respectively.  In  the African cohort  study by Gilks  et  al.34,  91% of 
pneumococcal serotypes incriminated in HIV-seropositive adults were 1, 3, 5, 7, 
19 and 23.
     Klebsiella pneumoniae, other members of Enterobacteriaceae family and 
Pseudomonas aeruginosa were present in 13,10 and 8% of cases respectively of 
confirmed pneumonia in a study by Hirschtick et al25.  Pseudomonas aeruginosa 
and S.aureus were cause of 25,9% of CAP in a study by Afessa et al40.  Levin et 
al41 recovered  S.aureus  in  23%  of  sputum  cultures  in  129  HIV  infected 
patients.Nocardia species42,Rhodococcus equi43,Streptomyces sp44 were found to 
be responsible for chronic pneumonia in AIDS. Pasteurella multocida45,Bordetella 
bronchiseptica46,Neisseria  sp47,Rocholimea  sp48,Corynebacterium 
pseudodiphtheriticum49,Legionella50 were equally the cause of pneumonia in HIV 
patients.Casedo et al51 showed lung involvement in AIDS patient with Salmonella 
septicaemia.
     Tuberculosis (TB) ranks as the most common infection seen in the developing 
countries.  About 55 to 89% of AIDS patients in India were found to be suffering  
from extensive pulmonary tuberculosis52,53.  It is estimated that world wide, nearly 
2 billion people are infected with Mycobacterium tuberculosis, 42 million are HIV 
infected and 5 to 6 million are dually infected with M. tuberculosis and HIV.  70% 
of HIV / TB dually infected people live in Sub-saharan Africa and 20% in Asia11.  
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Incidence of Fungal lower respiratory infection
Pneumocystis  jiroveci  previously  known  as  Pneumocystis  carinii  is  the  most 
common opportunistic infection in the West (>60%) and is found in patients with  
profound immunosuppression (CD 4 count < 200 cells/mm3).  Unlike in the west,  
the incidence of PCP is negligible in India (about 12%)11.  This is possibly due to 
poor index of suspicion and extensive use of cotrimoxazole for prophylaxis of 
PCP in HIV54.
Cryptococcus neoformans,  an  encapsulated yeast  is  the most  common deep 
seated  fungal infection in HIV patients.  Though the cryptococcal meningitis is 
the commonest  presentation, lungs is the primary site of infection. In a study
from Rwanda, Cryptococcus neoformans was isolated from sputum specimen of
37 HIV infected patients55.
Meyohas in his study on AIDS patients has isolated Aspergillus species from 
patients on anti-retroviral and steroid therapy56.  Shivananda in his study in 1992 
first reported 15.3% of isolates to be Aspergillus species57.  Geetha Lakshmi from 
Chennai has documented pulmonary aspergillosis in 36 HIV infected patients58.
Though pulmonary candidiasis is documented to be a very rare disease 
occurring in late stages of AIDS, oral and esophageal candidiasis is reported as 
second most common (58%) of opportunistic infection among HIV patients from 
India54.
Pencillium marneffei, a dimorphic fungus has been reported most commonly from 
South east Asian countries in HIV patients10.  Endemic mycosis such as 
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Histoplasmosis, Coccidioidomycosis, Blastomycosis are not seen very frequently 
in India11.
Incidence of mycoplasma in HIV 
     Mycoplasmas are commensals causing self-limiting and  clinically unimportant 
infections in human beings. Recent isolation of these organisms from adults with 
AIDS suggests that mycoplasmas might act as cofactors in patients infected with 
human immunodeficiency virus (HIV)59.                                                    
     The five  species of mycoplasmas identified as being associated withAIDS 
include Mycoplasma pneumoniae,M. fermentans, M. pirum, M. penetrans and M. 
genitalium60-61.  
      Teel et al 65 have reported that mycoplasmas colonized the respiratory tracts 
of 28 per cent of HIV-positive and 10.5 per cent of HIVnegative patients.
A detection rate of 12.5 per cent of mycoplasmas has been documented from 
bronchoalveolar lavage specimens of HIV infected patients which indicated that 
AIDS patients might be more often colonized or infected by mycoplasmas than 
HIV-negative patients or other immunocompromised persons 64.          
      Hjordis  62 isolated  M. pneumoniae  from respiratory specimens from AIDS 
patients  by  culture.  Ainsworth  et  al  63 have  detected  the  presence  of  M. 
fermentans in the respiratory tract of 27 per cent of the HIV population.     
     In another study mycoplasmas have been shown to colonize HIVpositive 
patients to a larger extent than HIV-negative individuals62. 
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Mycoplasma as cofactor in hiv progression66-71
      Luc Montagnier,co-discoverer of AIDS virus proposed that HIV may not work 
alone and mycoplasmas could be playing the key role in HIV progression68.
Pathogenic  Mycoplasma species  may influence HIV pathogenesis  by specific 
and direct activation or suppression of the immune system, the production of 
superantigens  with  subsequent  alterations  in  immune  responses,  or  their 
contribution to the oxidative stress observed in HIV-positive patients. Also, the 
development of AIDS may increase the susceptibility of HIV-infected patients for 
coinfection with  various  Mycoplasma species able to  bind HIV capsid protein 
gp120  permitting  adhesion  of  HIV  virions  to  the  mycoplasma  surface. 
Subsequently the HIV viruses could be transported directly to cells expressing 
CD4 receptors.  After binding to target cells, mycoplasmas can stimulate host cell  
activation by IL-1 and TNFa, which are known effectors for virus reproduction. In  
addition,  oligosaccharides  of  the  mycoplasmal  glycocalyx  may  protect  bound 
HIV-1  virons  from  host  immune  responses.  Antigen  similarities  between  the 
surface components of mycoplasmas and HIV-1 have led to speculation that they 
use similar mechanisms for cell entry.  For example, the HIV1 gp120 envelope 
glycoprotein and Mycoplasma  adhesion proteins share sequence homology and 
also have significant  similarity with  the CD4-binding site of  the class II  major 
histocompatibility complex (MHC) proteins. The interactions of microorganisms 
with MHC-related antigens on host cells could contribute to a number of possible 
outcomes,  including  T-cell  dysfunction,  T-cell  depletion,  T-cell  shift,  B-cell 
proliferation, hyperglobulinemia and antigen-presenting cell dysfunction. 
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Historical background
• The first mycoplasma to be isolated in culture was the bovine
pleuropneumonia  agent  now  known  as  Mycoplasma  mycoides  subsp. 
mycoides, which was described initially by Nocard andRoux in 1898  72 
• In the 1930s Klieneberger introduced the concept that mycoplasmas were
“L-forms”  of  bacteria  lacking  cell  walls  and  living  symbiotically  with  other,  
walled bacteria 73. 
• Dienes and Edsall detected the first mycoplasma isolated
from humans in a Bartholin’s gland abscess in 1937 74. This
mycoplasma was probably the organism we now know as Mycoplasma
hominis. 
• The organism eventually known to be Mycoplasma pneumoniae
was first isolated in tissue culture from the sputum of a patient with primary 
atypical pneumonia by Eaton et al in 1944, and thereafter it became known as 
the Eaton agent 75. 
• In 1961 Marmion and Goodburn postulated that the Eaton agent was a
PPLO and not a virus76,77.
• Chanock et al. succeeded in culturing the Eaton agent on cell-free
medium and proposed the taxonomic designation M. pneumoniae in 1963. 
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Mollicute taxonomy and classification
     The term “mycoplasma” (Greek; “mykes” - fungus and“plasma” - formed) 
emerged in the 1950s 78 and replaced the older PPLO terminology. In the 1960s, 
mycoplasmas  were  designated  members  of  a  class  named  Mollicutes,which 
derives from Latin words meaning soft (“mollis”) and skin (“cutis”).  Members of 
the class  Mollicutes  are characterized by their small  genomes consisting of a 
single circular chromosome containing 0.58 to 2.2 Mbp, a low G+C content (23 to 
40 mol%), and the permanent lack of a cell wall 80. 
       M. pneumoniae  is a member of the family  Mycoplasmataceae  and order 
Mycoplasmatales. Studies of 16S rRNA sequences suggest that mycoplasmas 
are most closely related to the gram-positive eubacterial subgroup that includes 
the bacilli, streptococci, and lactobacilli79.
Cell biology
      Mycoplasmas represent the smallest self-replicating organisms, in both 
cellular dimensions and genome size, that are capable of cell-free existence81. 
Individual spindle-shaped cells of M. pneumoniae are 1 to 2 µm long and 0.1 to 
0.2 µm wide, compared with a typical bacillus of 1 to 4 µm in length and 0.5 to 
1.0 µm in width. Accordingly, the M. pneumoniae cell volume is less than 5% of 
that of a typical bacillus. Cells may either divide by binary fission or first elongate 
to multinucleate filaments, which subsequently breakup to coccoid bodies
      The small size and volume of mycoplasmal cells allow them to pass through 
0.45µm-pore-size  filters  that  are  commonly used to  filter  sterilize  media.  The 
small cellular mass also means that mycoplasmas cannot be detected by light 
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microscopy,  and they do not  produce visible  turbidity  in  liquid  growth  media. 
Typical colonies of  M. pneumoniae, show fried egg appearance, rarely exceed 
100µm in diameter when cultivated on enriched medium and require examination 
under a stereomicroscope to visualize their morphological features. The genome 
of  M. pneumoniae was completely sequenced in 1996 and shown to consist of 
816,394  bp  with  687  genes.  Mollicutes  have  no  ability  to  synthesize 
peptidoglycan cell walls, since the genes responsible for these processes are not
present in the genome. The lack of a rigid cell wall confers pleomorphism on the 
cells and makes them unable to be classified as cocci or bacilli in the manner of 
conventional eubacteria. Sterols are necessary components of the triple-layered 
mycoplasmal  cell  membrane  that  provide  some  structural  support  to  the 
osmotically  fragile  mycoplasma.Maintenance  of  osmotic  stability  is  especially 
important  in  mollicutes due to  the lack of  a  rigid  cell  wall.  Another  structural 
component of the M.pneumoniae cell that is important for extracellular survival is 
aprotein network that provides a cytoskeleton to support thecell membrane
M. pneumoniae has been shown to bind  on glass and other solid surfaces, with 
the  organism  moving  with  the  attachment  organelle  at  the  leading  end. 
Neithergenomic analysis nor electron microscopy of M. pneumoniae
has demonstrated the presence of structures such asflagella or pili, suggesting 
that gliding motility occurs by an unknown mechanism involving the attachment 
organelle82.
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Pathogenesis
     M.pneumoniae is primarily an extracellular pathogen that depends on close 
association with host cells to survive, it has evolved a complex and specialized 
attachment  organelle  to  facilitate  its  parasitic  existence  .This  attachment 
organelle consists of a specialized tip structure with a central core of a dense 
rodlike central filament surrounded by a lucent space that is enveloped by an 
extension of the organism’s cell  membrane83,84.  The tip structure is actually a 
network of adhesins, interactive proteins, and adherence accessory proteins that 
cooperate structurally and functionally to mobilize and concentrate adhesions at 
the tip of the organism.
     The P1 adhesin85,86 is a 170-kDa protein concentrated in the attachment tip 
that is now known to be the major structure responsible for interaction of  M. 
pneumoniae with host cells. P30 87 is one of several additional proteins that have
been  implicated  in  the  adherence  process,  based  on  the  knowledge  that 
antibodies  developed  against  P30  can  block  M.  pneumoniae  hemadsorption 
Other  structures  produced  by  M.  pneumoniae  that  have  been  studied  as 
mediators in cytadherence in M. pneumoniae include proteins 88 HMW1, HMW2, 
HMW3, HMW4, HMW5, P90, and P65, which, in addition to P30, are believed to 
participate in the establishment of the polar structure. Once this polar structure
is established, an independently assembled complex of proteins B, C, and P1 is 
drawn to the structure to complete formation of the functional terminal attachment 
organelle .
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     Hydrogen peroxide and superoxide radicals are synthesized as a result of a 
flavin-terminated  electron  transport  chain  M.pneumoniae  act  in  concert  with 
endogenous toxic oxygen molecules generated by host cells to induce oxidative 
stress in the respiratory epithelium89.  Once  M. pneumoniae  reaches the lower 
respiratory tract, the organism may be opsonized by complement or antibodies 
macrophages become activated, begin phagocytosis, and undergo chemotactic 
migration  to  the  site  of  infection90.  High  percentages  of  neutrophils  and 
lymphocytes are present in alveolar fluid. Lymphocyte proliferation, production of  
immunoglobulins,  and release of  tumor necrosis  factoralpha (TNF-α),  gamma 
interferon (IFN-gamma), and various interleukins(including interleukin-1 [IL-1], IL-
2, IL-4, IL-5,IL-6, IL-8, IL-10, and IL-18) occurs91
Immune Response and Immunomodulatory Effects82
      Following an initial infection, the normal immune system responds by rapidly  
producing antibodies that peak after 3 to 6 weeks, followed by a gradual decline  
over months to years. 
     Elevation of  M. pneumoniae-specific IgM alone can often be interpreted as 
evidence of acute infection, since this antibody typically appears within 1 week of 
the initial infection and approximately 2 weeks before IgG antibody.
      In these cases, reinfection leads directly to an IgG response; therefore, the 
absence of a positive IgM test does rule out an acute infection. When it does 
occur, the IgM response may persist for months or years following infection and 
in  these cases a positive  IgM test  result  may not  reflect  a  current  or  recent  
infection.
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     IgA, while often overlooked as a diagnostic antibody class, may actually be a  
better indicator of recent infections in all age groups. IgA antibodies are produced 
early in the course of disease, rise quickly to peak levels, and decrease earlier 
than IgM or IgG.
     In addition to M. pneumoniae-specific antibodies, a variety of cross-reactive 
antibodies  may  develop  in  association  with  M.  pneumoniae  infection.  The 
extensive  sequence  homology  of  the  M.  pneumoniae  adhesin  proteins  and 
glycolipids  of  the  cell  membrane  with  mammalian  tissues  is  a  well-known 
example of molecular mimicry that may trigger autoimmune disorders that involve 
multiple organ systems through formation of antibodies against substances such 
as  myosin,  keratin,  fibrinogen,  brain,  liver,  kidney,  smooth  muscle,  and  lung 
tissues.
 
Antigenic Variation
High-frequency phase and antigenic variation of surface adhesin proteins made 
possible by DNA rearrangements in truncated and sequence-related copies of 
the  P1  adhesin  genes  that  are  dispersed  throughout  the  genome  has  been 
described for  M. pneumoniae82.   Recombinational events among the repetitive 
elements  themselves  and with  regions  of  the  three-gene  P1  adhesin  operon 
promote diversity and altered specificities and affinities and maximize the coding 
potential of the limited mycoplasma genome.
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Clinical significance
     M.pneumoniae is one of the many causes of a pneumonic process called 
atypical  pneumonia  along  with  several  bacterial  (Chlamydia  pneumoniae, 
Legionella  pneumophila)  and fungal  (Pneumocystis  carinii)  pathogens.   About 
10-30%  of  CAP  are  caused  by  M.pneumoniae  infection  and  these  cases 
represent only 3-10% of M.pneumoniae infection since tracheobronchitis or URT 
develop in most individuals or remain asymptomatic.  Infection usually occurs in 
school  age  children  >5  yrs,  adolescents,  young  adults  in  normal  population. 
Most  infection  in  these  are  minor  and  include  pharyngitis,  tracheobronchitis, 
bronchiolitis and croup.  Severe infection develops in immuno compromised HIV 
patients and elderly requiring hospitalization and  death may occur in some92.
Incubation period is 2-3 weeks.  Clinical presentation is usually insidious 
with the gradual onset of constitutional and pneumonic symptoms.  Fever of 101-
1020F with  chills,  malaise,  head ache,  sore throat,  nasal  congestion,  dry non 
productive  cough  appear  early  in  the  course.   The  leucocyte  count  is  often 
normal or elevated in immuno compromised patients.  LRT symptoms develop 
early and sputum becomes more mucoid or mucopurulent and hemoptysis  may 
also occur.  Gram stain smear of sputum show few to moderate amounts of PMN 
infective  cells  and  no  organisms.   With  the  onset  of  pneumonic  symptoms 
patients may feel as if they have severe cold and flu, yet will continue to function 
normally hence the application of the term walking pneumonia to this disease. 
On  the  chest  examination,  localized  bronchi  and  scattered  rales  are  usually 
detected  and  findings  on  chest  radiograph  are  consistent  with  diffuse 
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bronchopneumonia  generally  involving  multiple  lobes  of  the  lung  without 
consolidation.X  ray  pattern  may  vary  widely  and  may  show  peribronchial 
infiltrates,  atelectasis  and  hilar  lymphadenopathy.   Radiologic  findings  reveal 
more  than  the  physical  examinations  of  patients.   Other  pleuro-pulmonary 
complications  like  lung  abscess  and  pneumothorax  are  also  uncommon. 
Abnormalities  on  chest  films  resolve  more  slowly  in  10  days  to  6  weeks. 
Recurrence and relapses of pneumonia despite appropriate antimicrobial therapy 
can also occur in HIV patients.
Complications 
   Dermatologic,  cardiovascular,  musculoskeletal,  neurologic,  urologic, 
hepatobiliary  or  ocular  complications  can  occur.   Humoral  and  cellular 
Immunodeficiency   states in HIV patients predispose than to serious disease 
with M pneumonia.These patients may suffer repeated bouts of M pneumonia 
and  have  difficulty  in  eliminating  the  organism  from  respiratory  tract  despite 
adequate therapy.These patients often have upper and lower respiratory tract 
symptoms with few or no infiltration observed on chest X-ray and have significant 
complications. Fulminant dessiminated infection with multi system involvement is 
rare. But it has been reported.
 Media for culture of Mycoplasmas:
       Human mycoplasmas differ  in  their  optimal  pH for  growth  and in  the 
atmospheric  conditions that  are  required  for  successful  recovery  from clinical 
specimens.  Media for isolation of M.pneumoniae are buffered at an optimum pH 
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of  about  7.8.   The optimum temperature for  mycoplasmal  growth  is  35-370C. 
M.pneumoniae grows well in air or in an atmosphere of 95% N  and 5% CO2
Several  types  of  media  have  been  described  for  the  cultivation  of 
M.  pneumoniae.The medium recommended by Center  for  disease control  for 
isolation of  M. pneumoniae is Methylene blue glucose diphasic medium also 
known  as  PPLO  diphasic  medium.   This  medium  contains  PPLO 
(Pleuropneumonia  like  organism)  broth  and  agar,  yeast  extract,  serum 
supplements along with glucose, Methylene blue and phenol red.  The methylene 
blue in the medium inhibits the growth of other human mycoplasmas that may be 
found  in  respiratory  tract  making  the  medium  selective  for  M.  pneumoniae. 
During  growth  of  M.  pneumoniae the  medium becomes more  acidic  and the 
phenol red turns colour from salmon to yellow.  At the same time the organisms 
reduce the methylene blue and turn it  from blue to colourless.  Therefore the 
colour of the broth phase changes from purple to green or yellow green while the 
agar phase turns from purple colour to yellow or yellow orange.  This medium is 
used  in  conjunction  with  mycoplasma  glucose  agar(PPLO  agar)  medium. 
Colonies recovered either directly on this medium or from subcultures of positive 
broth  organ subjected to  inspection and identification  procedures.   Inorder  to 
avoid overgrowth by other pathogens a broad spectrum beta lactum antibiotic 
and an antifungal agent should be added to the medium.
      Another  medium  that  is  recommended  for  isolation  for  Mycoplasma 
pneumoniae from clinical specimens is Soy peptone (SP4 ) Broth and SP4 agar 
containing glucose.
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Isolation and identification
     The growth of M. pneumoniae from clinical specimens is detected by the  
ability of these organisms to produce acid from glucose.  Methylene blue glucose 
diphasic medium is inoculated with 0.2 ml of specimens and broth cultures are 
incubated at  350C with  caps tightened.   Tubes are inspected daily for  colour 
changes and turbidity for 4 weeks.  A slight, gradual shift in the pH indicator over  
8 to 15 days without gross turbidity suggests true positive cultures.  As soon as 
the colour changes are apparent, the broth is sub-cultured onto agar medium and 
incubated for 5 to 7 days at 350C.  Agar plates are sealed with air permeable 
cellophane tapes to prevent agar from drying out.  Inspection of agar under low 
power of microscope will reveal fried egg colonies.  In the absence of obvious 
colour change a blind subculture to agar media should be performed after 1 and 
3 weeks of  incubation.   A general  scheme for  isolation of  M.  pneumoniae is 
shown in chart.
     Human Mycoplasmas can be divided into  three groups on the basis  of 
utilization of three substrates – glucose, arginine and urea.  An enriched peptone 
basal medium containing yeast extract and serum supplemented with one of the 
three  substrates  with  a  pH  indicator  is  used.   Mycoplasma  pneumoniae 
metobolises glucose to produce lactic acid resulting in a shift to acidic pH.  
     Supravital  dyes such as Diene’s stain can be used for identification and 
characterization  of  the  colonies.   Tests  such as  Haemadsorption,  tetrazolium 
reduction, serological methods like epifluorescence procedure, growth inhibition 
test, immunoblot technique are also used for culture confirmation.  
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Serology
     Serology is an important tool for the diagnosis of M. pneumoniae infection. 
This is due to the ease of specimen collection and wide spread availability of 
serological test82.  Before the availability of more advanced serologic techniques, 
detection of cold agglutinins was a valuable tool for M. pneumoniae diagnosis96. 
The formation of cold agglutinins is the first humoral response to M. pneumoniae.  
However cold agglutinins are not reliable indicators as they are elevated in only 
50 to 60 % of patients.  Cross reactions may be induced by Ebstein-Barr virus,  
Cytomegalo  virus  and Klebsiella  pneumoniae,  malignancies  of  lymphoid  cells 
and auto-immune diseases93.  Complement fixation test(CF) once considered as 
standard for diagnosing M. pneumoniae is not widely used due to lack of both 
sensitivity  and  specificity.   More  advanced  alternative  to  CF  text  is  the 
microparticle agglutination assay (MAG), serodiamyco II.   The principle of this 
test  is  Haemagglutination  by specific  antibodies  to  mycoplasma pneumoniae. 
Erythrocytes  are  replaced  by  latex  particles  to  avoid  non-specific  reactions. 
Neither the CF test nor MAG enable differentiation between the antibody classes. 
So in order to achieve a specific diagnosis, separate detection of IgM, IgG, IgA 
antibodies  based  on  ELISA  principle  is  helpful.   A  rapid  card  based  assay 
(immunocard  mycoplasma)  has  also  been  developed  for  IgM  determination. 
Western  immunoblot  technique  for  M.  pneumoniae  has  also  been  recently 
developed.  Antigen detection techniques include, direct immuno-fluorescence, 
counter-immuno-electrophoresis,  immuno-blotting,  antigen  capture  enzyme 
immuno-assay97
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 Molecular techniques :
       Hybridisation assays provide a similar sensitivity as ELISA tests for antigen 
detection.  The Genprobe rapid system which involves a I 125 labelled DNA probe 
to an rRNA sequence specific for  M.pneumoniae was widely used before the 
application of PCR82,96.
     Nucleic  acid  amplification  by  PCR was  first  applied  for  M.pneumoniae 
diagnosis in 1989 by Bernet et al.  the main advantage of PCR is its superior 
sensitivity.   The sensitivity  may be  increased by  nested PCR which  may be 
required for  detection of  M.pneumoniae from extrapulmonary sites.   Multiplex 
PCR assays were designed for simultaneous detection of M. pneumoniae and 
other respiratory pathogens.  RNA amplification techniques are used for their  
high sensitivity  and detection of  this  nucleic  acid  is  more  indicative  of  viable 
mycoplasmas in clinical samples.
Antimicrobial susceptibilities and chemotherapy
     Infections  caused  by  M.pneumoniae  are  generally  treated  with  tetracycline  or 
erythromycin.  Because of the difficulty in culturing the organism, its slow growth rate 
and  the  lack  of  a  readily  available  method,  antimicrobial  susceptibility  testing  of 
M.pneumoniae is neither necessary nor appropriate.  Antimicrobial susceptibility testing 
of M.pneumoniae strains indicate that this organism is susceptible to a wide variety of 
antimicrobial agents including the quinolones that is cipfloxacin , levofloxacin, ofloxacin, 
gemifloxacin,  moxifloxacin,  clindamycin,  lincomycin,  tetracycline,  minocycline, 
doxycycline, erythromycin, streptomycin.  Some of the newer macrolide antibiotics such 
as  clarithromycin,  azithromycin,  flurithromycin  are  also  highly  active  against 
M.pneumoniae and show a very narrow range of minimal inhibitory concentrations.
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MATERIALS AND METHODS
     This prospective study was conducted on 100 HIV sero-positive patients 
attending the outpatient department or admitted in the Medical, Venereology  and 
Thoracic  Medicine  Departments  with  signs  of  lower  respiratory  infection  at 
Coimbatore  Medical  College  Hospital,  Coimbatore.   Specimens  for  the  study 
were collected over a period of one year and eight months from January 2005 to 
August 2006 .  
     Approval was obtained from the ethical committee prior to conducting the 
study and Informed consent from all patients under study was also obtained. 
• Inclusion criteria: 
      One hundred consecutive HIV sero-positive patients with symptoms and 
signs  suggestive  of  lower  respiratory  tract  infection  and  who  have  not 
received antibiotics for minimum of 2 weeks prior to this study.  
• Exclusion criteria: 
         Pediatric HIV sero-positive patients were excluded. 
     The name, age, sex, address, date of admission, inpatient number, clinical 
history of the patient were noted.  A thorough general examination and systemic 
examination of the patient was also done.
      HIV antibodies had been determined by Enzyme immuno assay by micro 
ELISA and confirmed by rapid  ELISA (Immuno chromatography and Immuno 
comb).
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      HIV seropositive patients were classified under different clinical stages 95 
according to the world health organization [WHO] guidelines  as mentioned in 
appendix i.
    Basic investigations such as Hb%, TC, DC, LFT, RFT, Blood Sugar, Urine 
complete examination, chest x-ray were also done.  
     CD4 cell counts assays done by flow-cytometry and immune status grading of 
the patients was done according to the  WHO 95 guidelines  as mentioned in 
appendix ii.   
   Sputum specimens  were  collected  for  bacterial,  fungal  and  mycobacterial 
cultures.
     Blood cultures were done for all patients to find out any bacteraemia.
Specimen collection and transport:
Samples collected:            Expectorated sputum
Induced sputum
Blood
Collection of expectorated sputum sample:
     The patient was instructed to cough out deeply and early morning sputum 
samples  on  three  consecutive  days  were  collected  in  sterile  wide  mouthed 
containers fitted with screw capped lids.
Collection of induced sputum sample:
     Induction of sputum was done using a nebuliser with 3% hypertonic saline for  
15 minutes and sputum was collected in sterile wide mouthed containers.
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Collection of blood sample:
After cleansing the site for venepuncture with betadine and 70% alcohol about 7  
ml of blood was collected and 5 ml was added to 50 ml of sterile brain heart  
infusion broth in blood culture bottles and remaining 2 ml of blood was used for 
serological tests.
     All the specimens were sent to the laboratory immediately after collection.
Safety precautions
• All sputum samples were potentially infectious and leak proof containers 
were used for collection and transportation of the samples.
• Biological safety cabinet level III was used for carrying out all procedures 
involving sputum and protective wears like mask, gloves etc   was used.  
•  Disinfection  of   the  sputum cups/  containers  by   treating  with  freshly 
prepared 1-2% sodium hypochlorite solution or autoclaving was followed.
Processing of sputum samples:
     Induced  sputum  was  used  for  detection  of  trophozoites  and  cysts  of 
P. jiroveci.
     Expectorated  sputum  samples  were  used  for  isolation  of  bacterial, 
mycobacterial and other fungal pathogens.
     The  quality  of  expectorated  sputum  was  assessed  by  macroscopic 
examination and microscopic examination.  Any sample that was thin, watery and 
with no purulent matter was considered unsuitable for further processing.  Gram 
stain was done and Brahmadhatan et al94 system  was used for assessing the 
quality of sputum samples as described in appendix iii.
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     The following staining methods were carried out for  detection of various 
organisms as described in the table below:
TABLE 2 – Stains used in our study
Methods Organisms
Gram stain
Ziehl Neelson stain (25% acid fast)
Ziehl Neelson stain (1% acid fast)
10% KOH mount
Indian ink preparation
Giemsa stain
Toluidine blue O stain
For assessing quality of sputum   & 
bacteria.
Mycobacteria
Nocardia
Fungi
Encapsulated yeasts
Fungi, P.jiroveci (trophozoites)
P. jiroveci (cysts)
Preparation and procedure for staining
Gram’s stain Procedure
1. Appropriate smear is made on a clean glass slide.
The smear is fixed by passing the slide over flame 2-3 times quickly.
Cover the slide with crystal violet solution and allow to act for about 30
seconds.
2. Pour off stain and holding the slide at an angle downwards pour on the
iodine solution on the slide so that it washes away the crystal violet.  Cover
the slide with fresh iodine solution and allow to act for 1 minute.  
      3.  Decolorize with 100% acetone. First tip off the iodine and hold the slide
at a steep slope. Then pour acetone over the slide from its upper end, so
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as to cover its whole surface. Decolorization is very rapid and is usually
complete in 2-3 seconds. After this period of contact, wash thoroughly
with water under a running tap
4.Apply the counterstain (0.5% safranine) for 30 seconds.
5. Wash with water and blot dry.
6. Examine the smear under oil immersion microscopy.
Ziehl Neelsen Staining Procedure
Reagents
–  Carbol fuchsin ---- 1%
–  Sulphuric acid ---- 25%
–  Methylene blue --- 0.1%
Method
1. Select a new, unscratched slide and label the slide with a laboratory serial 
number.
2. Make a smear from yellow purulent portion of the sputum using the jagged
end side of a bamboo stick. A good smear is spread evenly, 2cms x 3cms in size  
and is neither too thick nor too thin. The optimum thickness of the smear can be 
assessed by placing the  smear on a printed  matter,  the  print  should  be just 
readable through the smear.
3. Let the smear air-dry for 15-30 mins.
4. Fix  the  smear  by  passing  the  slide  over  the  flame  3-5  times  for  3-4 
seconds
each time.
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5. Place the fixed slide on the staining rack with the smeared side facing
upwards.
6. Pour filtered 1% carbol fuchsin over the slide so as to cover the entire
slide. Do not leave the carbol fuchsin on the slide for a long time (not more than 
5 mins.)
7. Heat the slide underneath until vapours start rising. Do not let carbol
fuchsin to boil or the slide to dry. Continue the process up to five minutes.
8. Allow the slide to cool for 5-7 minutes.
9. Gently rinse the slide with tap water to remove the excess carbol fuchsin
stain. At this point, the smear on the slide looks red in colour.
10.Decolour the stained slide by pouring 25% sulphuric acid on the slide
and leaving the acid for 2-4 mins.
11.Lightly wash away the free stain. Tip the slide to drain off the water.
If the slide is still red, reapply sulphuric acid for 1-3 mins, and rinse
gently with tap water.
12.Counter stain the slide by pouring 0.1% methylene blue solution on to
slide and let it stand for one min.
13.Gently rinse the slide with the tap water and tip the slide to drain off the
water.
14.Place the slide in the slide tray and allow it to dry.
15.Examine the slide under the microscope using 40 x objectives to select
the suitable area of the slide and examine under the 100 x lenses using
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a drop of immersion oil  for  the characteristic acid fast bacilli.  At least 100 oil  
immersion fields should be examined before declaring a smear as negative. In 
case of the scanty result, examine another 100 oil immersion fields.
TABLE 3 - Grading of sputum smears for AFB  was done as follows :
Examination 
findings
Result Grading Minimum No of 
fields
to be examined
More than 10 AFB 
per oil immersion Positive 3+ 20
1-10 AFB per oil 
immersion Positive 2+ 50
10-99 AFB per 
100 oil immersion Positive 1+ 100
1-9 AFB per 100 
oil immersion Scanty
Record exact 
number seen 200
No AFB per 100 
oil immersion 
fields
Negative 0 100
     A portion of the induced sputum specimen was washed with  saline and 
centrifuged at 1,500 rpm/10 minutes and the sediment was smeared and stained 
with Giemsa and Toluidine blue O and examined for cysts and trophozoites of P.  
jiroveci.
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Giemsa stain
Preparation and procedure for staining94
Preparation:
Giemsa powder 0.3 gm
Glycerine             25.0 ml
Acetone free methanol         25.0 ml
     The stock solution is diluted before use by adding 1 ml of stain to 10 ml of 
distilled water.
Procedure for staining:
1. Air dry thin films.
2. Fix in methanol for 1 minute
3. Wash in tap water  and flood the slide with  Giemsa diluted 1in 10 with 
buffered  distilled  water  (pH  7.2).   The  diluted  stain  must  be  freshly 
prepared each time.
4. Stain for 25 – 30 minutes.
5. Run tap water on to the slide to float off the stain and to prevent deposition 
of precipitate on the film.
6. Examine the film using X 100 objective.
Toluidine  blue O stain
Preparation and procedure for staining94
Preparation:
Toluidine Blue   0.3 gm
Concentrated HCl  2.0 ml
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Absolute alcohol    40.0 ml
Distilled water     60.0 ml
     Dissolve the stain in absolute alcohol.  Add 60 ml water and finally add 2 ml of 
conc. HCl.
Procedure for staining
1. Fix the smear in sulfation reagent ( 4.5 ml glacial  acetic acid + 1.5 ml 
concentrated sulfurinc acid) for 10 minutes.  Mix the reagent with a glass 
rod immediately and 5 minutes after.
2. Wash in a gentle stream of running tap water for 5 minutes.
3. Dip the slide in Toludine blue O stain, for 10 minutes.
4. Decolourise in 95% alcohol / absolute alcohol ( by taking in and out) 5 
secongs X 2.
5. Dip in xylene for cleaning – 10 seconds.
6. Mount with mounting fluid.
7. Observe with X 20 and X 40 objectives.
     The cyst wall stains violet to purple.  Thickenings and folds in cyst wall stain  
darker violet to purple.  Trophozoites and intracystic bodies are not stained.
Culture of sputum specimen
     The sputum samples were inoculated onto blood agar with 10% sheep blood, 
chocolate agar with 10% sheep blood, Mac Conkey agar.  Inoculated blood agar 
and chocolate agar plates were incubated at  37oC with  5-10% CO2 and Mac 
Conkey agar was incubated at 37oC.
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     The sputum was  inoculated onto Sabouraud’s Dextrose agar(SDA)  with 
antibiotics  and  SDA  without  antibiotics  in  duplicate  (  incubated  at  37oC and 
25oC).
     A portion of sputum specimen was decontaminated as per modified Petroff’s  
method as described94 and inoculated in Lowenstein Jensen’s (LJ) medium for 
culturing mycobacteria.  Inoculated LJ medium bottles were incubated at 37oC for 
6-8 weeks and observed for any growth.
     All the bacterial and fungal pathogens isolated were identified as per standard 
protocol92.   Antimicrobial  susceptibility  test  of  the  bacterial  isolates  to  various 
antibiotics was also done by Kirby Bauer’s disc diffusion method and antibiotic 
sensitivity  pattern  studied  according  to  clinical  laboratory  standards 
institute(CLSI).
Processing of sputum for culture of M. pneumoniae:
     Homogenisation of expectorated sputum specimen was done by repeatedly 
drawing  through  a  needle  and  syringe  as  chemical  treatments  for   sputum 
liquefaction are toxic for mycoplasma. 
        Isolation and identification of M. pneumoniae was performed as described 
by Koneman et al92.
Inoculation and Isolation: About 0.2 ml of homogenized sputum specimen was 
inoculated in a   tube of Mycoplasma selective diphasic culture medium.  The test 
tube  was  then  loosely  sealed  and  incubated  at  35oC for  upto  4  weeks  and 
inspected daily for turbidity and colour change.  (Broth phase – Violet to green or 
yellowish green.  Agar phase – purple to yellow or yellow orange).  If there was a 
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change in the colour of the medium with no increase in turbidity several drops of 
broth culture were subcultured onto a mycoplasma selective agar medium plate 
and was incubated at 35oC with 5% CO2 for another 7 days.  The agar surface 
observed for colonies after the fifth day under 10 X and 40 X magnification had 
the appearance of fried eggs.
     Blind subcultures of  broth to agar medium was done in the absence of 
obvious colour change after 1 and 3 weeks of incubation.
     Commercially available PPLO broth and agar base from Hi Media was used 
and PPLO diphasic medium and agar was prepared for selective isolation of M. 
pneumoniae and selective supplements added as follows:
Procedure for preparation of methylene blue glucose diphasic medium and 
agar PPLO diphasic medium and agar.  
(I) Base reagents for preparation of complete media
A. Mycoplasma base agar: This medium may be prepared using commercial 
PPLO agar base  according to the package instruction.Basal ingredients in PPLO 
agar base are as follows:
Beef heart infusion 250 gm
Peptone 10 gm
NaCl  5 gm
Purified agar 14 gm
Distilled water   1 ltr
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     Mix together and melt the agar in a boiling water bath.  Dispense in 70 ml 
aliquots and autoclave at 15 lbs for 15 minutes.  Store at 4oC.
B. Yeast extract:
1. Purchase commercial 25% yeast extract or prepare as follows – weigh out 250 
gm of active baker’s yeast and place in 1 ltr of distilled water.  Heat to boiling, 
cool  and filter  to  remove particular  matter.   Adjust  the pH to 8.0 and filter  – 
sterilize.
2. Yeast extract ( 20ml) is then mixed with uninactivated horse serum (10ml) in a 
2:1 ratio and frozen in 30 ml aliquots at -20oC.
C. Phenol red solution (0.4%): Phenol Red (1 g) is dissolved in 3 ml of 1 N 
NaOH and then 247 ml of distilled water is added.  Solution is filtered – sterilized 
and stored at 4 to 8oC.
D. Methylene Blue solution (1%): Methylene blue (1gm) is dissolved in 100 ml 
distilled water and autoclaved for 15 minutes.
E. Thallium acetate solution(10%): Thallium acetate (10g) is dissolved in 100 
ml of distilled water and filter sterilized.
F. Glucose solution: Glucose (50 gm) is dissolved in 100 ml distilled water and 
filter sterilized.
G. Penicillin solution: Penicillin powder is dissolved in distilled water to achieve 
a concentration of 1,00,000 units / ml.
(II) Methylene Blue – Glucose Diphasic Medium:
1. Melt 70 ml of mycoplasma agar in a boiling water bath.  Cool to 50oC and add 
30 ml prewarmed yeast extract serum.
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2. Add the following:
Methylene blue solution (1%) 0.1 ml
Phenol red solution (0.4%) 0.5 ml
Glucose solution 2.0 ml
Thallium acetate solution (10%) 0.25 ml
Penicillin solution 3.0 ml
3. Adjust the pH to 7.8 with sterile 1 N NaOH.
4. Dispense agar in 1 ml aliquots into sterile 13 X 100 mm screw capped tubes.
5. Mix 140 ml of mycoplasma broth (A, above, without agar) with 60 ml of yeast 
extract serum.  Add the following to this mixture
Methylene blue solution (1%) 0.2 ml
Phenol red solution 1.0 ml
Glucose solution 4.0 ml
Thallium acetate solution (10%) 6.0 ml
Pencillin solution 0.5ml
  6. Adjust the pH to 7.8 with sterile 1 N NaOH. Dispense 2.0 ml into each of the 
tubes containing the solidified agar medium.
(III) Mycoplasma glucose agar medium
1. Melt 70 ml of mycoplasma agar in a boiling water bath.  Cool to 50oC.
2. Prewarm 30 ml of yeast extract serum and mix with the agar medium
3. Aseptically add the following  reagents:
Glucose solution 2.0 ml
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Thallium acetate solution (10%) 0.25 ml
Penicillin solution 3.0 ml
4. Adjust the pH to 7.8 with sterile 1 N NaOH.
5. Dispense 6 ml of medium into 60 X 15 mm Petri dishes.  Allow to cool.  Store 
media at 4oC. 
Identification: Presumptive identification of colonies of mycoplasma 
pneumoniae was done by the following methods:
1.Diene’s stain, 2.Haemadsorption, 3.Glucose fermentation, 4.Hydrolysis of urea, 
5.Arginine hydrolysis.
Diene’s stain procedure for identification of mycoplasmas:
I. Principle: Mycoplasma colonies from  are easily identified by observing typical  
colonies on agar medium.  Visualization of colony morphology is facilitated by 
application of Diene’s  stain directly to agar surface.
     Diene’s stain is a nonspecific stain that imparts a contrasting appearance of 
mycoplasma colonies on agar, allowing easier visualization of colony morphology 
and characteristics.
II. Reagents: A. Modified Diene’s stain ( stock solution)
Methylene blue  2.5 gms
Azure blue  1.2 gm
Maltose 10.0 gm
Na2CO3  0.25 gm
Distilled water            100.0 ml
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     Diene’s stain working solution is prepared by diluting an aliquot of the stock 
solution 1:3 with distilled water.        
(III) Procedure:
1. Flood an agar plate containing mycoplasma growth with 1 ml of Diene’s 
stain working solution.
2. Immediately rinse the agar surface with distilled water to remove the stain.
3. Decolorize the medium by adding 1 ml of 95% ethanol.  Leave in contact 
with the agar for 1 minute, then remove.  Repeat the wash step a second 
time.
4. Rinse the plate with distilled water and allow to dry.
5. Observe for colonies under the low power of a microscope ( 50 to100X).
IV Results: A. Interpretation:
     Mycoplasmas with the ‘fried – egg’ colony morphology will stain with a dark  
blue centre and light blue periphery and will appear highly granular.  The agar 
background will be clear or slightly violet.
     Mycoplasma other than M. pneumoniae will remain stained; M. pneumoniae 
reduces the methylene blue after a time and will become colorless.
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Hemadsorption test for identification of mycoplasma pneumoniae
(I) Principle: Among the respiratory Mycoplasmas, M. pneumoniae is the only 
species  that  will  specifically  absorb  red  blood  cells.   This  property,therefore, 
provides a method for the presumptive identification of M. pneumoniae.
     When colony growth is noted on mycoplasma isolation media inoculated with 
respiratory tract specimens a suspension of guinea pig erythrocytes is placed on 
the agar surface for a given time and then washed off.  M. pneumoniae colonies 
will adsorb some of the red cells to the colony surface.
(II) Reagents:
A. Mycoplasma glucose agar with suspicious colonies present
B. Washed guinea pig erythrocytes ( 0.2 – 0.4%) suspended in mycoplasma 
broth medium.
(III) Procedure:
1. Flood the surface of the agar plate with 2 ml of red cell suspension.
2. Incubate the plate at 35oC for 30 minutes and rotate the plate occasionally 
to prevent the red cells from settling out.
3. Wash the surface of the plate three time with 3 ml of mycoplasma broth by 
gently rotating the plate.  Remove wash fluid by aspiration with a pipet.
4. Examine  the  colonies  at  50  to  100X  magnification  under  a  dissecting 
microscope.
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(IV) Results: 
A. Interpretation:
1.  Positive  test:  Colonies  with  red  cells  adsorbed  onto  the  surface  – 
M. pneumoniae
2. Negative test: Colonies with no red cells adsorbed – Mycoplasma species, not 
M. pneumoniae.
Glucose fermentation:
     Sterile PPLO broth with 0.5% glucose with pH 7.8 prepared as described 
above and about 2 ml of medium was dispersed in 13 X100 mm sterile screen 
capped tubes.
     0.25 ml of positive broth culture was inoculated and incubated aerobically at 
37oC for 10 days.  Fermentation status was checked daily.  A change in colour 
from purple to yellow was noted.
Arginine hydrolysis
     Sterile screw capped tubes containing 2 ml of Arginine broth with 0.25% 
arginine at pH 7.0 was inoculated with 0.25 ml of broth culture of the isolate and 
incubated aerobically at 37oC for 10 days.  The result of hydrolysis was checked 
daily by observing a colour change from purple to red.
Urea hydrolysis
     Ten  percent  Urea  was  incorporated  into  PPLO  broth  media  at  a  final 
concentration of 1% in the media and pH of the medium was adjusted to 6.5.  
Screw capped tubes with sterile medium was inoculated with 0.25 ml of broth 
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culture  of  the  isolate  and  incubated  aerobically  at  35oC for  10  days.   Urea 
breakdown was checked based on observing colour change from purple to red.
Serological tests
     About  2  ml  of  blood  was  centrifuged  and  serum  was  separated  and 
commercially  available  Mycoplasma  pneumoniae  IgM  TMB  ELISA  (Bio  Rad 
Laboratories) was done according to manufacturer’s instructions supplied in the 
kit.
 Principle : When antigens bound to the solid phase are brought into contact 
with  a  patient's  serum,  antigen  specific  antibody,  if  present,  will  bind  to  the 
antigen  on  the  solid  phase  forming  antigen-antibody  complexes.   Excess 
antibody is removed by washing.  This is followed by the addition of goat anti-
human IgM globulin conjugated with horseradish peroxidase, which then binds to 
the antibody-antigen complexes.  The excess conjugate is removed by washing, 
followed  by  the  addition  of  substrate  and  chromogen,  Tetramethylbenzidine 
(TMB). If specific antibody to the antigen is present in the patient's serum, a blue 
color develops.  When the enzymatic reaction is stopped with 1N H2SO4, the 
contents  of  the  wells  turn  yellow.   The  color,  which  is  proportional  to  the 
concentration of antibody in the serum, is read on ELISA microwell plate reader 
at  450nm.Serological  response  of  the  patients  against  mycoplasma  antigen 
coated to microtitre wells is thus determined.
     Serum diluent used contained goat antihuman IgG to adsorb and remove 
competing IgG.Cut off calibrators were used to calibrate the assay to account for 
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day  to  day  fluctuations  in  temperature.Horse  radish  peroxidase  conjugate 
containing goat antihuman IgM and tetra methyl benzidine substrate were used.
Assay Procedure
1.  Place the desired number of strips into a microwell frame. Allow six (6) 
Control/Cutoff  Calibrator  determinations  (one  Negative  Control,  three 
Cutoff  Calibrators,  one  High  Positive  Control,  and  one  Low  Positive 
Control) per run.  A reagent blank (RB) should be run on each assay.  
2. Dilute test sera, Cutoff Calibrator and Control sera 1:81 (e.g., 10 µL + 800 
µL) in Serum Diluent Plus
3. To individual wells add 100  µL of diluted patient sera, Cutoff Calibrator 
and Control sera. Add 100 µL of Serum Diluent Plus to the reagent blank 
well. 
4. Incubate each well at room temperature (21° to 25° C) for 30 minutes + 2 
minutes.
5. Using automated washing equipment add 250-300  µL of  diluted Wash 
Buffer to each well.  Repeat the wash procedure  four times (for a total of 
five washes) for automated equipment
6. Add 100 µL Conjugate to each well, including the reagent blank well.  
7. Incubate each well 30 minutes + 2 minutes at room temperature (21° to 
25° C).
8. Repeat Wash as described in Step 5.
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9. Add 100  µL Chromogen/Substrate solution (TMB) solution to each well, 
including reagent blank well10. Incubate  each  well  10  minutes  +  2 
minutes at room temperature (21° to 25° C).
11. Stop reaction by addition of 100 µL of Stop Solution (1N H2SO4) following 
the same order as Chromogen/Substate addition, including reagent blank 
well.  Tap the plate gently along the outsides to mix contents of the wells. 
The plate may be held up to one hour after addition of the Stop Solution 
before reading.
12. The developed color should be read on an ELISA plate reader equipped 
with a 450 nm filter.  
Calculations
1. Mean Cutoff Calibrator O.D. (Optical Density) - Calculate the mean O.D. 
value for the Cutoff Calibrator from the three Calibrator determinations.  
2. Correction Factor - To account for day-to-day fluctuations in assay activity 
due to room temperature and timing, a Correction Factor is determined for 
each lot of kits.  The Correction Factor is printed on the Calibrator vial.
3. Cutoff  Calibrator Value - The Cutoff Calibrator Value for each assay is 
determined  by  multiplying  the  Correction  Factor  by  the  mean  Cutoff 
Calibrator O.D. 
4. ISR Value - Immune Status Ratio (ISR) for each specimen is calculated by 
dividing the specimen O.D. Value by the Cutoff Calibrator Value 
 Immune Status Ratio (ISR) was calculated as per manufacturer’s instructions.
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TABLE 4 -(ISR) Immune Status Ratio Interpretation:
ISRValue Results Interpretation
</= 0.9
0.9 – 1.09
>/= 1.10
Negative
Equivocal
Positive
No detectable IgM 
antibody to Mp suggests 
no current immunological 
exposure to Mycoplasma 
pneumoniae.
Immunological exposure 
cannot be assessed. 
Samples should be 
retested by an alternate 
method (IFA).  If results 
remain equivocal upon 
further testing an 
additional sample should 
be taken.
Significant level of 
detectable IgM antibody 
to mycoplasma. 
Indicative of current or 
recent infection.
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RESULTS
 This study included 100 HIV seropositive patients with lower respiratory 
tract infections.
TABLE 5 - AGE & SEX-WISE DISTRIBUTION OF CASES
Sex No. of 
patients
Age in years
Range Mean Median Percentage
Male 71 27 – 55 37 38 71
Female 29 28 – 65 36 35 29
     Among the 100 cases, 71 were males with range of age from 27 – 55 years 
and mean age 37.6 and 29 were females with range of age from 28 – 65 years 
and mean age of 36.2.
TABLE 6 - AGE GROUPS UNDER STUDY
Age in years
21 – 30 31 – 40 41 – 50 51 – 60 > 60
Male 14 35 20 2 -
Female 8 17 3 - 1
Total 22 52 23 2 1
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     Among the 71 males,14 were in 21 -30 year age group, 35 were in 31 – 40 
year age group, 2 were in 51-60 year age group and among the females, 8 were 
in 21 – 30 year age group, 17 were in 31 -40 year age group and 2 were in 40 – 
50 year and 1 female was 65 years of age.
TABLE 7 - PATHOGENS ISOLATED FROM HIV SEROPOSITIVE PATIENTS
  
Pathogens isolated No. of HIV infected patients 
N=100
Mycobacteria 21
Mycoplasma pneumoniae 19
Other bacteria 54
Fungi 19
Polymicrobial 29
Total no. of culture positive cases 70
Total no. of pathogens isolated 113
     Among the 100 cases included in the study, pathogens could be isolated from 
70 patients.  Polymicrobial isolation was found in 29 cases. 
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TABLE 8 - AGE & SEXWISE DISTRIBUTION OF CULTURE POSITIVE CASES 
IS AS FOLLOWS
21 – 30 31 – 40 41 -50 51 – 60 > 60
Males 12 24 12 2 -
Females 6 11 2 - 1
Total 18 35 14 2 1
           Etiological agent could be identified in more number of patients in 21 – 30 
and 31 – 40 year age groups.     
     Among  the  study  cases  most  common  clinical  presentations  were 
cough(95%), dyspnea(80%) , chest pain(82%) , fever(76%) , night sweats(73%) ,  
Loss of appetite(70%) , haemoptysis  ,  neutropenia(56%) , anaemia(26%) and 
thrombocytopenia(32%) and 46% of cases were on antiretroviral therapy.
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TABLE 9 - BACTERIAL PATHOGENS ISOLATED FROM HIV SERO-
POSITIVE PATIENTS
Pathogens isolated Number 
of 
isolates
N=73
In single / 
Mono-
microbial
In 
combination
/ 
Polymicrobi
al
Klebsiella pneumoniae 22 12 (54.5%) 10 (45.4%)
Mycoplasma pneumoniae 19 4 (21%) 15 (79%)
Pseudomonas 
aeruginosa
10 5(50%) 5 (50%)
Staphylococcus aureus 9 3 (33%) 6 (67%)
Streptococcus 
pneumoniae
8 5 (62%) 3 (38%)
Moraxella catarrhalis 3 1 (33%) 2 (67%)
Haemophilus influenzae 1 1 -
Escherichia coli 1 - 1
    The most  common bacteria  isolated were  Klebsiella  pneumoniae (n=22), 
Pseudomonas aeruginosa (n=10), Staphylococcus aureus (n=9), Streptococcus 
pneumoniae (n=8) which constituted 30%, 13%, 12%, 11% of the total bacterial  
isolates respectively  and the numbers they were  isolated in  combination with 
other organisms were as shown in the table.
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TABLE 10 - MYCOBACTERIA ISOLATED FROM HIV SERO-POSITIVE 
PATIENTS
Mycobacteria isolated No. of 
cases
In 
single
In 
combina-
tion
Mycobacterium 
tuberculosis
20 4 16
Atypical mycobacteria 1 - 1
     21 Mycobacteria were isolated from our study.  Most of the organisms (16) 
were polymicrobial isolations.  One atypical mycobacterium was isolated from a 
patient with  stage III  disease and CD4 count of  115 cells/mm3.   The atypical 
mycobacterium  was  presumptively  identified  as  Mycobacterium  avium 
intracellulare.
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TABLE 11 - FUNGAL PATHOGENS ISOLATED FROM HIV SERO-POSITIVE 
PATIENTS
Pathogens isolated
No. of 
cases
In single / 
Monomicrobial
In combination / 
Polymicrobial
Candida species 15 - 15
Aspergillus niger 2 1 1
Cryptococcus neoformans 1 - 1
Penicillium marneffei 1 - 1
     19 pathogenic fungi were isolated in our study, out of which, 15 were Candida 
species.  Gram stained smears of patients showing pseudohyphae and yeast 
cells were  only considered as pathogenic isolates.   Sputum examination was 
done for 3 consecutive days to confirm the fungal isolates.
     Cryptococcus  neoformans  was  isolated  in  a  case  diagnosed  to  have 
pulmonary  tuberculosis  on  anti  tuberculous  treatment  and  that  patient 
succumbed to death.  This patient had CD4 cell count of 120 cells / mm3.
     Penicillium marneffei was also isolated in a patient with CD4 cell count of 125 
cells/mm3.
     Aspergillus niger was isolated in two cases and both cases had CD 4 counts < 
200  cells  /mm3.   This  was  confirmed  by  repeated  sputum  culture  on  3 
consecutive days.
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TABLE 12 - IMMUNOSTAGING IN STUDY CASES AND SPUTUM CULTURE 
POSITIVE CASES
Levels of 
Immuno-
suppression
CD4 count
Cells/ mm3
Total No. of 
cases
N=100
No. of culture 
positive cases
N=70
Severe IS <200 43 38
Advanced IS 200 – 349 52 29
Mild IS 350 – 499 5 3
No significant IS > 500 0 0
TABLE 13 - HIV CLINICAL STAGING IN STUDY CASES AND SPUTUM 
CULTURE POSITIVE CASES
HIV stage Total No. of cases
N=100
No. of culture positive 
cases N=70
I 2 0
II 43 30
III 51 36
IV 4 4
     Revised WHO clinical staging and immunological staging for classification of 
HIV  seropositive  cases  was  used  in  our  study.According  to  this  67(97%)  of 
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culture  positive  cases  were  in  stages  of  advanced  and  severe 
immunosuppression  with  CD4  counts  of  200-349  and  <200  cells  /mm3 
respectively.
     30 sputum culture positive cases were in clinigal stage II and 36 cases were  
in clinical stage III and 4 cases were in stage IV and this constituted a total of  
94% in clinical stages II and III.
TABLE 14 - AGE AND SEX-WISE DISTRIBUTION OF CULTURE POSITIVE 
CASES OF  MYCOPLASMA PNEUMONIAE IN HIV SERO-POSITIVE 
PATIENTS
Age group in 
years
No. of males
N=71
Culture +ive 
for 
Mycoplasma 
pneumoniae
No. of 
females
N=29
Culture +ive 
for 
Mycoplasma 
pneumoniae
No.
N=14
% No.
N=5
%
21 – 30 14 3 21.4 8 1 12.5
31 – 40 35 7 20           17 3 17.6
41 – 50 20 4 20 3 1 33.3
>50 2 - - 1 - -
    
Mycoplasma pneumoniae was isolated in 19 cases, out of which 14 were males 
and 5 were females.Mycoplasma isolation was found to be more in n=10 in 31-40 
year  age group than in other age groups.M.salivarium was also isolated in 2 
cases but it was excluded as a commensal.
60
TABLE 15 – CO-PATHOGENS ISOLATED ALONG WITH  MYCOPLASMA 
PNEUMONIAE 
Pathogens isolated
Mycoplasma 
pneumoniae 
positive cases 
N = 19
Mycoplasma 
pneumoniae negative 
cases 
N = 81
Klebsiella pneumoniae 5 ( 26% ) 17 (20.9%) 
Pseudomonas aeruginosa 3 ( 16% ) 7  (8.6%)
Staphylococcus aureus 3 ( 16% ) 6 (7.4%)
Moraxella catarrhalis 0 ( 0% ) 3 (3.7%)
Streptococcus pneumoniae 1 ( 5% ) 7 ( 8.6%)
Mycobacteria 6 ( 32% ) 15 ( 18.5%)
Aspergillus niger 1 ( 5% ) 1 ( 1.2% )
Candida species 5 ( 26% ) 10 ( 12.3% )
   
     Klebsiella pneumoniae (n=5),Pseudomonas aeruginosa(n =3),Staphylococcus 
aureus(n =3),Mycobacteria(n=6) were the most common co-pathogens isolated 
along with Mycoplasma pneumoniae positive cases in combination.
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TABLE 16 - ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF BACTERIAL 
ISOLATES
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Klebsiella pneumonia 
(N=22)
10 14 14 15 14 15 5 - - - -
Pseudomonas 
aeroginosa (N=10)
4 5 6 7 4 5 3 - - - -
Haemophillus 
influenzae (N=1)
1 1 1 1 1 1 1 - - - -
Escherichia  coli 
(N=1)
1 1 1 1 1 1 0 - - - -
Staphylococcus 
aureus (N=9)
- 5 5 6 6 8 4 5 4 9 4
Streptococcus 
pneumoniae (N=8)
- 7 5 6 7 8 6 7 7 8 7
Moraxella  catarrhalis 
(N=3)
- 2 2 2 2 2 1 2 1 2 1
     The above values mentioned in the table are the number of isolates found to  
be sensitive to the corresponding antibiotics as above.
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      Klebsiella pneumoniae was 63% and 69% sensitive to fluoroquinolones and 
third generation cephalosporins respectively and 30% were extended spectrum 
betalactamase producing strains.
      Pseudomonas  aeruginosa  was  70%  sensitive  to  fluoroquinolones. 
Staphylococcus  aureus was  89% sensitive  to  third  generation cephalosporins 
and 24% were methicillin resistant strains.
     Streptococcus  pneumoniae  was  87%  sensitive  to  fluoroquinolones, 
erythromycin and cephalosporins.
     Antibiotic Sensitivity pattern of other bacterial isolates are as mentioned in the  
table above.
TABLE 17 - CD4 CELL COUNT IN CULTURE 
POSITIVE CASES OF MYCOPLASMA PNEUMONIAE
HIV STAGING IN CULTURE  POSITIVE CASES OF MYCOPLASMA 
PNEUMONIAE
HIV stage No. of culture positive cases
N=19
I 0 ( 0% )
II 4 ( 21% )
 
III 11 ( 57.8% )
IV 4 (21%)
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     12(63%) cases with  sputum culture positive for M.pneumoniae had CD4 
counts <100 cells /mm3  and all  these cases had mixed infections with  other 
organisms and 11(57.8%) , 4(21%) of mycoplasma positive cases had stage III 
and stage IV disease respectively.
TABLE 18 - MYCOPLASMA PNEUMONIAE IgM ELISA POSITIVE CASES 
WITH CULTURE POSITIVE CASES
Mp IgM ELISA positive 
cases (N)
Mp IgM ELISA positive 
and Mp culture positive 
cases(N)
MpIgM ELISA positive 
and Mp culture 
negative cases(N)
23 19 4
    The incidence of mycoplasma pneumoniae was 19% in  our study group. 
Mycoplasma pneumoniae IgM ELISA showed positivity in 23% of cases among 
which sputum culture for mycoplasma pneumoniae was positive in 19%.
     Blood cultures were found to be positive (n=16) in our study cases along with  
sputum  culture  positivity.  The  most  common  isolate  was  Klebsiella 
pneumoniae(N=8) followed by Pseudomonas aeruginosa(N=3), Staphylococcus 
aureus(N=5).
      Antibiotic sensitivity pattern of the isolates was similar to the isolates from 
sputum culture positivity.
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TABLE 19 - CLINICORADIOLOGICAL FINDINGS OF PATHOGENIC 
ISOLATES AMONG HIV SERO-POSITIVE PATIENTS
Clinical Diagnosis Radiology Isolates
Broncho pneumonia
  N = 10
Peribronchial 
infiltrates
Interstitial infiltrates
Staphylococcus aureus
Mycoplasma pneumoniae
Moraxella catarhalis
Aspergillus niger
Haemophillus influenzae
Lobar pneumonia
  N = 9
Consolidation
With cavitations
With pneumothorax
With pleural effusion
Klebsiella pneumoniae
Streptococcus pneumoniae
Pseudomonas aeroginosa
Strepococcus pneumoniae
Mycoplasma pneumoniae
Staphylococcus aureus
Pulmonary tuberculosis
  N = 24
Bilateral extensive 
cavitatory lesions
Consolidation
Fibrous cavity with 
military mottling
With pleural effusion
Atypical mycobacterium
Mycobacterium tuberculosis
Cryptococcus neoformans
Mycobacterium tuberculosis
Mycoplasma pneumoniae
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Bronchitis
  N = 15
Increased 
bronchovascular 
marking
Klebsiella pneumoniae
Pseudomonas aerogenosa
Bronchial asthma
  N = 12
Increased broncho-
vascular markings
Emphysema changes
Mycoplasma pneumoniae   
Streptococcus pneumoniae
     Peribronchial infiltrates(10%),consolidation(9%),fibrous cavity(5%),increased 
bronchovascular  markings(15%),emphysematous  changes(10%)  and  pleural 
effusion(4%) were found in our study cases.
     Staphylococcus aureus and Mycoplasma pneumoniae isolations were more 
common  in  patients  with  peribronchial  infiltrates.  Klebsiella 
pneumoniae,Streptococcus  pneumoniae  were  more  common  isolations  in 
patients  with  consolidation.Mycobacterium  tuberculosis  was  isolated  more 
commonly in patients with fibrous cavity and the other findings are as seen in the 
table.
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DISCUSSION
Among the opportunistic infections associated with HIV, diseases like pneumonia of bacterial  
origin are encountered more frequently 10.  
     The importance of  respiratory  infections in HIV patients  is  well  documented3.   The true 
incidence of these infections is difficult to assess and varies with the population surveyed5.  In the 
present  study,  of  the 100 HIV infected patients,  the etiologic  agent could  be identified in 70 
patients.
Bacterial isolates :
     In our study, the bacterial and fungal isolates from the HIV infected patients were of varied  
etiology and the bacterial isolates(N=54) excluding M.pneumoniae and M.tuberculosis constituted 
47.7% among which K. pneumoniae isolated in 40.7%, P. aeruginosa in 18.5%, S. aureus in 
16.6% and S. pneumoniae in 14.8% were the most common bacterial pathogens isolated.  M. 
pneumoniae constituted 26% among the bacterial pathogens isolated(N=73).  
     As per  the figures from National  AIDS control  organization (NACO),  bacterial  infections 
constituted 7% of opportunistic infections and the common organisms encountered in pulmonary 
infections were S. pneumoniae, H. influenzae,            S. aureus2.  
     Tchmaran96 in  his study on the lung diseases due to common bacteria in  HIV infected 
individuals in African adults noted 81% of infections due to                    S. pneumoniae and  
reported it  to be the most offending pathogen in  HIV infected patients.   Of all  the infections 
reported risk or susceptibility to infections with encapsulated organisms such as S. pneumoniae 
and C. neoformans appear to be the most. 
       Falco et al 97in their study on bacterial pneumoniae in HIV infected patients have reported S. 
pneumoniae in (34%), H. influenzae in 18% as the most common causative agents.  
67
     Bensel et al98 reported S. pneumoniae and H. influenzae in 35.8% and 22.6% respectively.
     Klebsiella pneumoniae , Pseudomonas aerugenosa and Staphylococcus aureus infections are 
usually community acquired in HIV infected patients3.       
      Hirschtick et al28 noted K. pneumoniae, P. aeruginosa in 13% and 8% of cases of confirmed 
pneumonia (LRTI).  
     Dropulic99 in his study on the clinical manifestations of P. aeruginosa infection among patients 
with AIDS found that of the 73 episodes of P. aeruginosa infections, 13 were that of pneumonia.  
     Shailaja et al  2  in their study on LRTI in HIV infected patients have reported 9.68% of the 
isolates to be P. aeruginosa and also associated it as an important cause of mortality.
    Moraxella catarrhalis is generally considered as a commensal in the upper respiratory tract of  
adults and its isolation from sputum is often considered as normal flora of the oropharaynx.  This 
appears to be a misconception as Sehgal and Shainy100 in 1994 reported this organisms as the 
second  most  common  isolate  from  patients  suffering  from  LRTI.   In  the  present  study,  M. 
catarrhalis was repeatedly isolated from three samples collected in 3 consecutive days from 3 
patients and it constituted 4% of the bacterial isolates.  Gram stained sputum smears of all the 
these patients had numerous pus cells with many Gram negative cocci in pairs.  Escherichia coli 
and Haemophilus influenzae constituted 4% of bacterial isolates in our study.
Mycobacterial isolates 
     About 55-89% of AIDS cases in India were found to be suffering from extensive pulmonary 
tuberculosis4,52,53.   In our study,  M. tuberculosis was isolated in 20 HIV infected patients and 
constituted 21.2% among the bacterial isolates and atypical mycobacterium was isolated in one 
the HIV infected patients and was presumptively identified as Mycobacterium avium intracellulare. 
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     Shailaja  et  al  2in  their  study  have  reported  M.  tuberculosis  in  42.89%  and  atypical 
mycobacteria  as  one  of  the  isolates.   However  atypical  mycobacteria  has  been  commonly 
reported from AIDS cases from Western countries,  it  has been scarcely reported from India. 
Shailaja et al has reported atypical mycobacteria as one of the isolates in her study.
Fungal isolates 
     Fungal infections occurs most often with other pathogens in immunocompromised patients 3. 
In  the  present  study,  19  fungal  pathogens  were  isolated.   In  our  study  Candida  species, 
Cryptococcus  neoformans,  Aspergillus  niger,  Penicillium  marneffei  constituted  15  (78.9%),  1 
(5.2%), 2 (10.5%),              1 (5.2%), of the fungal isolates respectively.  These patients had  
repeated isolation of  the above mentioned fungi with  the sputum samples collected on three 
consecutive days.  The Gram stained smear also revealed pseudohyphae with yeast cells, and 
hence the possibility of esophageal colonization was ruled out.  
     Penicillium marneffei, a dimorphic fungus, has been most commonly reported from AIDS 
cases in South east Asian countries10.  In our study, it was isolated in one of the HIV patients and 
it  was  confirmed based on  yeast  to  mould  conversion  and  presence  of  red  pigment  on the 
reverse.  Cryptococcus neoformans was also isolated from one of our patients in our study. 
      Shanker et al101 reported Candida species in 80% of their isolates.     
      Shivananda 57 in his study in 1992 on 825 patients with pulmonary infections found 15.39% of 
isolates to be Aspergillus species.  Of these A. fumigatus was 11.15%, A. niger was 3.2% and A. 
flavus was 0.96%.  
     Geethalakshmi et al58 has documented pulmonary aspergillosis in 36 samples.  
      Pankajalakshmi  et  al102 emphasized  the  emergence  of  candiadiasis,  cryptococcosis, 
aspergillosis, penicilliosis and other phacohyphomycosis in HIV infected patients.  
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     PCP is more prevalent in Western countries.Very few Indian studies have reported P. jiroveci.  
Three cases of PCP have been reported from Delhi103.  In our study, an attempt was made to 
demonstrate the presence of trophozoites / cysts of P. jiroveci  in induced sputum.  However,  
none of the sputum samples were positive for PCP.  Elizabeth Mathai104 has reported PC in 5 of 
15 AIDS patients from broncho-alveolar lavage specimens.  
Mycoplasma isolates
     Though the role of mycoplasmas as cofactors in HIV has been proved, studies about the 
incidence of M. pneumoniae in India is scarce.In our study M. pneumoniae was isolated from 
19% of the bacterial isolates. 
     Shankar et al 106 have reported M. pneumoniae in 36% of AIDS patients.
     Dev AB et al105have reported 35.5% of M. pneumoniae  infections in CAP.  He also noted tht  
60% of M. pneumoniae infections has occurred in HIV infected patients.     
     Louise D Teel  65  has reported mycoplasma species in 28.2% of  HIV patients from BAL 
cultures. 
     Stool et al 64 have reported that mycoplasma colonized 12.5% of HIV infected patients. 
      Shankar et al106 reported a higher incidence of mycoplasma pneumoniae in younger and older 
age group in a similar study.  In our study incidence of M. pneumoniae was found to be more 
common in 31 – 40 year age group. 
Serology:     
     Though direct isolation of mycoplasma is considered the gold standard, Mycoplasma culture is  
notoriously  difficult  and  laborious.   Hence  detection  of  IgM  antibodies  against  Mycoplasma 
pneumoniae antigen by ELISA has been done in our study as it is highly sensitive and specific  
and indicates recent infection.  In our study, M. pneumoniae IgM ELISA was positive in 23% of 
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HIV infected patients.  Out of these 19% of HIV infected patients had sputum culture positive for 
M. pneumoniae.  In a study of M. pneumoniae at Yemen by Al Moyed108, IgM antibodies against 
M. pneumoniae in sputum were detected in 20.7% of cases out of which 9.6% were the culture  
positive cases.  
     Phillipe tuppin et al107 have reported M.pneumoniae IgM ELISA positivity in 15% of the cases.  
Polymicrobial isolates
      Polymicrobial  isolation  was  found  to  be  common  in  Mycoplasma  positive  HIV  cases.  
Klebsiella  pneumoniae  (20.9%),  Mycobacterium tuberculosis  (18.5%),  Staphylococcus  aureus 
(7.4%), Pseudomonas aeruginosa (8.6%) were found to be more in mycoplasma negative cases 
than mycoplasma positive ones.  
     This was similar to the study reported by Shanker et al106.  
Clinico-radiological findings
     In our study, 95% had cough as a presenting symptom followed by dyspnoea, chest pain,  
fever, night sweats, loss of appetite and haemoptysis.  Dorigo Zetsma et al 110 in their study have 
reported similar symptomatology.
     In our study, about 10% were clinically diagnosed to have bronchopneumonia, 9% had lobar 
pneumonia,  24%  had  pulmonary  tuberculosis,  15%  had  bronchitis  and  12%  had  bronchial 
asthma.  
     Almoyed et al108 have reported 41.6% cases with bronchopneumonia, 36% cases with lobar 
pneumonia, 32% cases with bronchial asthma, 28% with bronchitis, 23% with tuberculosis and 
20% with COPD. 
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     In our study , 94% of sputum culture positive cases were in clinical stages II 
and III  and   about 78.9% of Mycoplasma pneumoniae culture positive cases 
were in III and IV stages. This was similar to study by Shankar et al106. 
     Chest radiographic findings in sputum culture positive cases in our group were as follows: 
Peribronchial  infiltrates  (10%),  Consolidation  (9%),  Fibrous  cavity  with  military  mottling  (5%), 
Increased  bronchovascular  markings  (15%),  emphysematous  changes(10%),  pleural  effusion 
(4%).  Shailaja et al 2 and Robert Craven et al 111 have also reported similar findings in their group.
     Peribronchial infiltrates and pleural effusion were commonly associated with  Staphylococcus 
aureus   and  Mycoplasma  pneumoniae  infections.   Consolidation  was  seen  commonly  with 
Klebsiella pneumoniae and Streptococcus pnuemoniae infections.  Mycobacterium tuberculosis 
was isolated in patients with cavitatory leisions and fibrosis.  
Haematological findings   
     In our study various hematological, immunological findings were correlated similar to the study 
by Shanker et al106.  In our study, 97% of culture positive cases were in stages of advanced and 
severe immunosuppression with CD4 counts of 200-349 and <200 cells /mm3 respectively. They 
have reported that mean CD4 counts of culture positive cases for Mycoplasma pneumoniae was 
76 cells/microliter, and they had also noted that co infections were more common in Mycoplasma 
pneumoniae culture positive cases in AIDS cases.  
     In our study the mean CD4 count was 96 cells / mm3  in Mycoplasma pneumoniae culture 
positive cases and 63% of culture positive cases for Mycoplasma pneumoniae had CD4 count <  
100 cells/mm3.
     CD 4 cell count was less than 200 cells/mm3 in 15% of  Mycoplasma culture positive cases in 
a study by Phillipe Tuppin et al 107
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      In  our  study,  56%  of  cases  had  neutropenia,  26%  had  anaemia  and  32%  had 
thrombocytopenia.  Phillipe Tuppin et al 107 reported neutropenia, anaemia, thrombocytopenia  in 
48%, 20% and 28% respectively in their study group.  
Antibiotic susceptibility
     Klebsiella pneumoniae was 63% and 69% sensitive to fluoroquinolones and 
third generation cephalosporins respectively and 30% were extended spectrum 
betalactamase producing strains.
      Pseudomonas  aeruginosa  was  70%  sensitive  to  fluoroquinolones. 
Staphylococcus  aureus was  89% sensitive  to  third  generation cephalosporins 
and 24% were methicillin resistant strains.
     Streptococcus  pneumoniae  was  87%  sensitive  to  fluoroquinolones, 
erythromycin  and  cephalosporins.These  values  were  similar  to  the  study  by 
Shailaja et al2 and Aroma oberoi et al109.
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SUMMARY 
• One hundred consecutive HIV seropositive patients with lower respiratory 
infection  were  studied  during  the  period  from January  2005 to  August 
2006 at Coimbatore Medical College Hospital.
• There were 71 males and 29 females in the study.
• Etiological agent was made out in 70 cases and a total of 113 pathogens 
were isolated from sputum culture.
• Out of the 113 pathogenic isolates bacterial isolates constituted 47.7%.
• Klebsiella pneumoniae(40.7%) was the most common bacterial pathogen 
isolated.   This  was  followed  by  pseudomonas  aeruginosa(18.5%), 
Staphylococcus aureus(16.6%) and Streptococcus pneumoniae(14.8%).
• Mycobacterium tuberculosis was isolated from 20% of the cases.
• Fungal  pathogens  isolated  were  Candida  sp(78.9%),Cryptococcus 
neoformans(5.2%),  Aspergillus  niger(10.5%)  and  Penicilllium 
marneffei(5.2%).
• The incidence of M.pneumoniae infection was 19% in HIV seropositive 
patients  with  lower  respiratory  infections.Sputum  culture  positivity  for 
M.pneumoniae was higher in 31-40 year age group.
• M. pneumoniae IgM ELISA positivity was found in 23% of the cases.
• 63%  of  culture  positive  cases  for  Mycoplasma  pneumoniae  had  CD4 
count <100 cells /mm3
• 78.9% of Mycoplasma pneumoniae culture positive cases were in III and 
IV clinical stages
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• 97% of culture positive cases were  in  stages of advanced and severe 
immunosuppression  with  CD4 counts  of  200-349 and <200 cells  /mm3 
respectively.94% of sputum culture positive cases were in clinical stage II 
and III.    
• Klebsiella pneumoniae was 63% and 69% sensitive to fluoroquinolones 
and third generation cephalosporins respectively and 30% were extended 
spectrum betalactamase producing strains.
• Pseudomonas aeruginosa was 70% sensitive to fluoroquinolones.
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CONCLUSION
     This prospective study on one hundred HIV seropositive patients with lower 
respiratory  infections  was  conducted  in  order  to  record  clinical  and 
microbiological observations to study bacterial  and fungal etiology of LRTI,the 
incidence  of  M.pneumoniae  infection,the  significance  of  serology  in 
M.pneumoniae diagnosis,the hematological and clinico radiological findings and 
the antibiotic susceptibility pattern of the bacterial isolates.
     Klebsiella  pneumoniae,  Pseudomonas  aeruginosa  and  Staphylococcus 
aureus  were  the  most  common  bacterial  isolates.M.tuberculosis  was  also 
commonly isolated.
     Candida sp, Aspergillus sp, Cryptococcus neofomans, Penicillium marneffei 
were the fungal isolates.
     We were  able  to  isolate  and  identify  M.pneumoniae  in  culture  and the  
incidence was 19%.
     M.pneumoniae IgM ELISA was positive in all the culture positive cases.Hence 
diagnosis of M.pneumoniae by IgM ELISA was found to be significant and hence 
its use has to be considered as an important diagnostic tool as the culture of 
M.pneumoniae is time consuming and laborious.
     CD4 lymphocyte count and clinical staging of the patients and radiological and 
haemotological findings were also helpful in diagnosing LRTI in our study cases. 
As  the  CD4  lymphocyte  count  declined  HIV  seropositive  patients  were 
susceptible to a variety of bacterial and fungal lower respiratory pathogens.
     Antibiotic sensitivity testing of the common bacterial isolates were also done. 
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     HIV seropositive patients especially with advanced disease had increased 
susceptibility to lower respiratory infections.These bacterial and fungal pathogens 
causing lower respiratory infections were the cause of significant morbidity and 
mortality.
     Early recognition of the onset of lower respiratory infections and identification 
of etiological agents associated with it are essential for treatment to succeed.The 
prime  concern  is  to  institute  prompt  antibiotic  prophylactic  treatment  while 
pursuing the laboratory diagnosis.
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